Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KYXATA vs COLESEVELAM HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).
Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.
Pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise capacity and delay clinical worsening,Treatment of PAH in combination with other PAH therapies
Adjunctive therapy to diet and exercise for reduction of elevated LDL cholesterol in adults with primary hyperlipidemia,Monotherapy or combination therapy for homozygous familial hypercholesterolemia,Adjunctive therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Pediatric primary hyperlipidemia
KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.
3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.
Terminal elimination half-life is 12–15 hours in adults with normal renal function; extends to 22–30 hours in moderate renal impairment (Cr Cl 30–50 m L/min) and up to 48 hours in severe impairment (Cr Cl <30 m L/min).
Not applicable as colesevelam is not absorbed; it acts locally in the gastrointestinal tract.
Primarily hepatic via CYP3A4 and CYP2C19; minor contribution from UGT1A1, UGT1A3, UGT1A9. Active metabolite (M14) via dealkylation.
Colesevelam is not systemically absorbed (<0.05%) and undergoes negligible metabolism.
Renal excretion accounts for approximately 70% of elimination (60% unchanged, 10% as metabolites); biliary/fecal excretion accounts for 25% (primarily as metabolites); minor metabolic clearance (5%) via CYP3A4.
Colesevelam is not absorbed systemically; it is excreted unchanged in the feces via biliary elimination. No renal excretion occurs.
88–92% bound to albumin and alpha-1-acid glycoprotein.
0% (not absorbed; no systemic protein binding).
0.8–1.2 L/kg, indicating extensive extravascular distribution into tissues including brain and myocardium.
Not applicable; drug is not systemically absorbed and remains confined to the gastrointestinal lumen.
Oral: 35–45% (due to first-pass metabolism); IM: 80–90%; IV: 100%.
<0.1% after oral administration; essentially not absorbed.
No dosage adjustment is required for renal impairment. Landiolol is minimally renally excreted (approximately 1% unchanged). However, use caution in patients with severe renal impairment (Cr Cl < 30 m L/min) due to limited data.
No dose adjustment required for renal impairment; not systemically absorbed.
For mild hepatic impairment (Child-Pugh Class A): No dosage adjustment needed. For moderate to severe hepatic impairment (Child-Pugh Class B or C): Reduce initial infusion rate to 0.05 mg/kg/min and titrate cautiously; maximum infusion rate of 0.2 mg/kg/min is recommended due to reduced clearance.
No dose adjustment required for hepatic impairment.
Weight-based dosing: Loading dose of 0.125 mg/kg intravenously over 1 minute, followed by continuous infusion starting at 0.05 mg/kg/min, titrated to effect. Maximum infusion rate is 0.3 mg/kg/min. Safety and efficacy established in pediatric patients aged 1 to <18 years.
Not approved for pediatric patients; safety and efficacy not established.
Elderly patients (≥65 years): Start at the lower end of the dosing range (initial infusion rate of 0.05 mg/kg/min) and titrate slowly due to potential decreased hepatic function and increased sensitivity. No specific dose adjustment mandated, but monitor heart rate and blood pressure closely.
No specific dose adjustment; use with caution due to potential for constipation and gastrointestinal obstruction.
Embryofetal toxicity: Must be avoided in pregnancy; females of reproductive potential must use reliable contraception and have monthly pregnancy tests.
No FDA black box warning.
Hepatotoxicity (requires monthly liver function monitoring); fluid retention (peripheral edema, may require diuretics); hematologic changes (hemoglobin decrease, requires periodic monitoring); pulmonary veno-occlusive disease (PVOD) should be excluded.
May cause hypertriglyceridemia (monitor triglycerides),Risk of fat-soluble vitamin deficiency (Vitamins A, D, E, K) with prolonged use,May reduce absorption of: oral contraceptives, cyclosporine, warfarin, thyroid hormone, and other drugs (administer 4 hours before or after Colesevelam),Patients with hemorrhoids or history of severe GI obstruction risk,May cause constipation, dyspepsia, and abdominal pain
Pregnancy (absolute); hypersensitivity to macitentan or any component; concomitant use with strong CYP3A4 inducers (e.g., rifampin) (relative); severe hepatic impairment (Child-Pugh C) (relative).
Bowel obstruction or history of bowel obstruction,Hypertriglyceridemia-induced pancreatitis,Elevated serum triglycerides >500 mg/d L,Hypersensitivity to colesevelam or any component
Avoid alcohol and grapefruit juice. High-fat meals may delay absorption; take on empty stomach for consistent effect.
Take with meals to enhance bile acid binding. Avoid high-fat meals that may reduce efficacy. Colesevelam may interfere with absorption of fat-soluble vitamins (A, D, E, K); consider supplementation if long-term use. Grapefruit juice has no documented interaction.
No human data; animal studies not available. Risk cannot be excluded; avoid in pregnancy unless benefit outweighs potential fetal risk.
Colesevelam hydrochloride is not systemically absorbed (<0.05% oral bioavailability). No fetal risk is expected. No adequate and well-controlled studies in pregnant women. Based on animal studies, no evidence of harm at doses up to 1.5 times human dose. Insufficient data for first trimester; however, given negligible absorption, teratogenic risk is considered negligible across all trimesters.
No human data; M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise against breastfeeding during therapy.
Colesevelam is not absorbed systemically; therefore, excretion into breast milk is negligible. M/P ratio: not applicable. Considered compatible with breastfeeding by most sources.
No pharmacokinetic data in pregnancy; no dose adjustment guidelines available. Use with caution and therapeutic drug monitoring if applicable.
No dosing adjustment is necessary. Colesevelam's pharmacokinetics are unaffected by pregnancy due to negligible systemic absorption. Dose should be based on clinical response to hyperlipidemia. Standard adult dosing: 3 tablets (625 mg each) twice daily or 6 tablets once daily with food and liquid.
KYXATA (potassium oxyrate) is a CNS depressant; avoid concurrent use with alcohol or other sedatives. Monitor for respiratory depression, especially in elderly or COPD patients. Taper dose to prevent withdrawal seizures. Not a controlled substance but carries abuse potential.
Colesevelam is a bile acid sequestrant that reduces LDL-C and improves glycemic control in type 2 diabetes. Administer with meals to maximize bile acid binding. Monitor triglycerides as levels may increase. Separate dosing from other medications (e.g., levothyroxine, warfarin) by at least 4 hours to avoid reduced absorption. Can be mixed with water, fruit juice, or soft foods.
Take exactly as prescribed; do not increase dose or frequency.,Avoid driving or operating machinery until you know how KYXATA affects you.,Do not drink alcohol while taking this medication.,Do not stop suddenly; abrupt discontinuation may cause seizures.,Report any unusual changes in mood, thoughts, or behavior.,Store at room temperature, away from moisture and heat.
Take this medication with a meal and at least 4 hours after any other medications.,Mix powder with 4-8 ounces of water, fruit juice, or soft food (e.g., applesauce) and consume within 24 hours.,Do not take without food; it may cause stomach upset.,Common side effects include constipation, gas, and indigestion; drink plenty of fluids and increase fiber intake.,This medication can increase triglyceride levels; your doctor will monitor your blood.,Inform your doctor if you have a history of pancreatitis or gallbladder disease.,Keep out of reach of children and store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KYXATA vs COLESEVELAM HYDROCHLORIDE, answered by our medical review team.
KYXATA is a Unknown that works by Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).. COLESEVELAM HYDROCHLORIDE is a Bile Acid Sequestrant that works by Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KYXATA and COLESEVELAM HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KYXATA is: KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.. The standard adult dose of COLESEVELAM HYDROCHLORIDE is: 3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KYXATA and COLESEVELAM HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KYXATA is classified as Category C. No human data; animal studies not available. Risk cannot be excluded; avoid in pregnancy unless benefit outweighs potential fetal risk.. COLESEVELAM HYDROCHLORIDE is classified as Category A/B. Colesevelam hydrochloride is not systemically absorbed (<0.05% oral bioavailability). No fetal risk is expected. No adequate and well-controlled studies in pregnant women. Based on. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.